Statements (47)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:age |
gptkb:Person
adults |
| gptkbp:approves |
gptkb:1980
|
| gptkbp:average_temperature |
2 to 8 degrees Celsius
|
| gptkbp:clinical_trial |
Phase IV
|
| gptkbp:contraindication |
immunocompromised individuals
severe allergic reaction to vaccine components |
| gptkbp:dosage_form |
1 m L
|
| gptkbp:duration |
long-lasting immunity
|
| gptkbp:effective_date |
FDA approved
|
| gptkbp:healthcare |
important for public health
|
| https://www.w3.org/2000/01/rdf-schema#label |
Imovax Rabies
|
| gptkbp:is_used_for |
rabies prevention
|
| gptkbp:is_vulnerable_to |
gptkb:item
varies by region generally safe developed in the 20th century refrigerated ongoing studies post-marketing surveillance WHO guidelines global availability available in pharmacies post-exposure prophylaxis subunit vaccine high efficacy pre-exposure prophylaxis multiple doses for post-exposure reduced rabies cases single dose for pre-exposure |
| gptkbp:manager |
intramuscular injection
|
| gptkbp:manufacturer |
gptkb:Sanofi_Pasteur
|
| gptkbp:side_effect |
headache
muscle pain nausea fever pain at injection site rare severe reactions |
| gptkbp:suitable_for |
veterinarians
animal bites travelers to endemic areas laboratory workers handling rabies virus |
| gptkbp:targets |
rabies
|
| gptkbp:type |
inactivated virus vaccine
|
| gptkbp:bfsParent |
gptkb:rabies_vaccine
|
| gptkbp:bfsLayer |
5
|